Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Prostate Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 103 articles: HTML format Text format

Single Articles

January 2012
1. ROSS RW , Galsky MD, Febbo P, Barry M, et al
   Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer : A Prostate Cancer Clinical Trials Consortium trial.
   Cancer. 2012 Jan 26. doi: 10.1002/cncr.27416.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. ZAFARANA G , Ishkanian AS, Malloff CA, Locke JA, et al
   Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.
   Cancer. 2012 Jan 26. doi: 10.1002/cncr.26729.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. HOPPE BS , Nichols RC, Henderson RH, Morris CG, et al
   Erectile function, incontinence, and other quality of life outcomes following proton therapy for prostate cancer in men 60 years old and younger.
   Cancer. 2012 Jan 17. doi: 10.1002/cncr.27398.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. TAKSLER GB , Keating NL, Cutler DM
   Explaining racial differences in prostate cancer mortality.
   Cancer. 2012 Jan 13. doi: 10.1002/cncr.27379.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
5. KEEGAN KA , Dall'era MA, Durbin-Johnson B, Evans CP, et al
   Active surveillance for prostate cancer compared with immediate treatment: An economic analysis.
   Cancer. 2011 Dec 16. doi: 10.1002/cncr.26688.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. MONK JP , Halabi S, Picus J, Hussain A, et al
   Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782.
   Cancer. 2011 Dec 16. doi: 10.1002/cncr.26732.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. MARCELLA SW , David A, Ohman-Strickland PA, Carson J, et al
   Statin use and fatal prostate cancer: A matched case-control study.
   Cancer. 2011 Dec 16. doi: 10.1002/cncr.26720.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. SONG L , Mishel M, Bensen JT, Chen RC, et al
   How does health literacy affect quality of life among men with newly diagnosed clinically localized prostate cancer?: Findings from the North Carolina-Louisiana Prostate Cancer Project (PCaP).
   Cancer. 2011 Dec 16. doi: 10.1002/cncr.26713.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
9. COOPERBERG MR , Hilton JF, Carroll PR
   The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy.
   Cancer. 2011;117:5039-46.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. SHAHINIAN VB
    Androgen deprivation for prostate cancer: The case for "first, do no harm"
    Cancer. 2011 Nov 9. doi: 10.1002/cncr.26624.
    PubMed     Text format     Related articles   
    
    
    
    
11. EHDAIE B , Atoria CL, Gupta A, Feifer A, et al
    Androgen deprivation and thromboembolic events in men with prostate cancer.
    Cancer. 2011 Nov 9. doi: 10.1002/cncr.26623.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. AHMED HU , Cathcart P, Chalasani V, Williams A, et al
    Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy.
    Cancer. 2011 Nov 9. doi: 10.1002/cncr.26631.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. SILBERSTEIN JL , Vickers AJ, Power NE, Fine SW, et al
    Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy.
    Cancer. 2011;117:4855-60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. SPENCER B
    Utilization and expense of adjuvant cancer therapies following radical prostatectomy.
    Cancer. 2011;117:4810-1.
    PubMed     Text format     Related articles   
    
    
    
    
15. WILLIAMS SB , Gu X, Lipsitz SR, Nguyen PL, et al
    Utilization and expense of adjuvant cancer therapies following radical prostatectomy.
    Cancer. 2011;117:4846-54.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
16. GARCIA JA , Rini BI
    Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead.
    Cancer. 2011 Oct 28. doi: 10.1002/cncr.26582.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. LOWRANCE WT , Eastham JA, Yee DS, Laudone VP, et al
    Costs of medical care after open or minimally invasive prostate cancer surgery: A population-based analysis.
    Cancer. 2011 Oct 24. doi: 10.1002/cncr.26609.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. KOSCUISZKA M , Hatcher D, Christos PJ, Rose AE, et al
    Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment.
    Cancer. 2011 Oct 21. doi: 10.1002/cncr.26619.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. WILLIAMS SB , Salami S, Regan MM, Ankerst DP, et al
    Selective detection of histologically aggressive prostate cancer: An Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial.
    Cancer. 2011 Oct 17. doi: 10.1002/cncr.26396.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. SCOSYREV E , Messing EM, Mohile S, Golijanin D, et al
    Prostate cancer in the elderly: Frequency of advanced disease at presentation and disease-specific mortality.
    Cancer. 2011 Oct 17. doi: 10.1002/cncr.26392.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
21. SCHOVER LR , Canada AL, Yuan Y, Sui D, et al
    A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment.
    Cancer. 2011 Sep 26. doi: 10.1002/cncr.26308.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. PRINTZ C
    Hair loss at 20 associated with prostate cancer risk later in life.
    Cancer. 2011;117:4105.
    PubMed     Text format     Related articles   
    
    
    
    
23. GROOME PA , Rohland SL, Siemens DR, Brundage MD, et al
    Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates.
    Cancer. 2011;117:3943-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. COTTER SE , Chen MH, Moul JW, Lee WR, et al
    Salvage radiation in men after prostate-specific antigen failure and the risk of death.
    Cancer. 2011;117:3925-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. FEIFER AH , Elkin EB, Lowrance WT, Denton B, et al
    Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy.
    Cancer. 2011;117:3933-42.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. SALONIA A , Gallina A, Briganti A, Abdollah F, et al
    Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy.
    Cancer. 2011;117:3953-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
27. KAPADIA NS , Olson K, Sandler HM, Feng FY, et al
    Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer.
    Cancer. 2011 Aug 26. doi: 10.1002/cncr.26498.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. ANTONARAKIS ES , Zahurak ML, Lin J, Keizman D, et al
    Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: Combined analysis of 4 phase II trials.
    Cancer. 2011 Aug 25. doi: 10.1002/cncr.26437.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. TIMILSHINA N , Breunis H, Alibhai S
    Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer.
    Cancer. 2011 Aug 25. doi: 10.1002/cncr.26477.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. PRINTZ C
    ASCO highlights new findings on cancer screening discoveries connected to ovarian, cervical, and prostate cancers.
    Cancer. 2011;117:3627-8.
    PubMed     Text format     Related articles   
    
    
    
    
31. PRASAD SM , Gu X, Lipsitz SR, Nguyen PL, et al
    Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States.
    Cancer. 2011 Aug 5. doi: 10.1002/cncr.26416.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
32. ARAUJO JC , Mathew P, Armstrong AJ, Braud EL, et al
    Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study.
    Cancer. 2011 Jul 25. doi: 10.1002/cncr.26204.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. SCHRODER FH , Roobol MJ
    Selective detection of aggressive prostate cancer.
    Cancer. 2011 Jul 15. doi: 10.1002/cncr.26385.
    PubMed     Text format     Related articles   
    
    
    
    
34. HALL MJ , Ruth K, Giri VN
    Rates and predictors of colorectal cancer screening by race among motivated men participating in a prostate cancer risk assessment program.
    Cancer. 2011 Jul 12. doi: 10.1002/cncr.26315.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. SUARDI N , Gallina A, Capitanio U, Salonia A, et al
    Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients.
    Cancer. 2011 Jul 12. doi: 10.1002/cncr.26234.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. BOORJIAN SA , Karnes RJ, Viterbo R, Rangel LJ, et al
    Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
    Cancer. 2011;117:2883-91.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. PRINTZ C
    Molecular predicator of metastatic cancer identified.
    Cancer. 2011;117:2829.
    PubMed     Text format     Related articles   
    
    
    
    
38. PRINTZ C
    Smoking studies produce new findings regarding breast and lung cancer link.
    Cancer. 2011;117:2828-9.
    PubMed     Text format     Related articles   
    
    
    
    
39. KEATING NL , O'Malley AJ, Murabito JM, Smith KP, et al
    Minimal social network effects evident in cancer screening behavior.
    Cancer. 2011;117:3045-52.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
40. KLEIN EA
    What is the best way to treat high-risk prostate cancer?
    Cancer. 2011 Jun 30. doi: 10.1002/cncr.26281.
    PubMed     Text format     Related articles   
    
    
    
    
41. PARIKH R , Sher DJ
    Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: A decision analysis.
    Cancer. 2011 Jun 30. doi: 10.1002/cncr.26272.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. POLLACK CE , Bekelman JE, Liao KJ, Armstrong K, et al
    Hospital racial composition and the treatment of localized prostate cancer.
    Cancer. 2011 Jun 20. doi: 10.1002/cncr.26232.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. KRUSER TJ , Jarrard DF, Graf AK, Hedican SP, et al
    Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.
    Cancer. 2011;117:2629-36.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. KATTAN MW , Gerds TA
    Making and evaluating a statistical prediction model for the absolute risk of prostate cancer recurrence.
    Cancer. 2011 Jun 3. doi: 10.1002/cncr.26174.
    PubMed     Text format     Related articles   
    
    
    
    
45. MANDAL S , Abebe F, Chaudhary J
    2'-5' oligoadenylate synthetase 1 polymorphism is associated with prostate cancer.
    Cancer. 2011 Jun 2. doi: 10.1002/cncr.26219.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
46. VAN HEMELRIJCK M , Garmo H, Holmberg L, Walldius G, et al
    Prostate cancer risk in the Swedish AMORIS study: The interplay among triglycerides, total cholesterol, and glucose.
    Cancer. 2011;117:2086-95.
    PubMed     Text format     Related articles   
    
    
    
    
47. SMITH MR , Cook R, Lee KA, Nelson JB, et al
    Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
    Cancer. 2011;117:2077-85.
    PubMed     Text format     Related articles   
    
    
    
    
48. DASKIVICH TJ , Chamie K, Kwan L, Labo J, et al
    Overtreatment of men with low-risk prostate cancer and significant comorbidity.
    Cancer. 2011;117:2058-66.
    PubMed     Text format     Related articles   
    
    
    
    
49. CHU DI , Freedland SJ
    Metabolic risk factors in prostate cancer.
    Cancer. 2011;117:2020-3.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
50. PRINTZ C
    Studies report risks associated with androgen deprivation therapy.
    Cancer. 2011;117:1559.
    PubMed     Text format     Related articles   
    
    
    
    
51. SALONIA A , Gallina A, Briganti A, Suardi N, et al
    Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy.
    Cancer. 2011 Apr 14. doi: 10.1002/cncr.26136.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. 
    Overtreatment of men with low-risk prostate cancer and significant comorbidity.
    Cancer. 2011 Apr 8. doi: 10.1002/cncr.26131.
    PubMed     Text format     Related articles   
    
    
    
    
53. 
    Reply to overtreatment of men with low-risk prostate cancer and significant comorbidity.
    Cancer. 2011 Apr 8. doi: 10.1002/cncr.26125.
    PubMed     Text format     Related articles   
    
    
    
    
54. BEEBE-DIMMER J , Shahinian V
    Tackling overtreatment of prostate cancer : The role of comorbidity.
    Cancer. 2011 Apr 8. doi: 10.1002/cncr.26106.
    PubMed     Text format     Related articles   
    
    
    
    
55. DASKIVICH TJ , Chamie K, Kwan L, Labo J, et al
    Comorbidity and competing risks for mortality in men with prostate cancer.
    Cancer. 2011 Apr 8. doi: 10.1002/cncr.26104.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. ALICIKUS ZA , Yamada Y, Zhang Z, Pei X, et al
    Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.
    Cancer. 2011;117:1429-37.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
57. HAYN MH , Orom H, Shavers VL, Sanda MG, et al
    Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer.
    Cancer. 2011 Mar 31. doi: 10.1002/cncr.26103.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. ELLIOTT SP , Jarosek SL, Alanee SR, Konety BR, et al
    Three-dimensional external beam radiotherapy for prostate cancer increases the risk of hip fracture.
    Cancer. 2011 Mar 16. doi: 10.1002/cncr.25994.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. ANEES M , Horak P, El-Gazzar A, Susani M, et al
    Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.
    Cancer. 2011;117:1172-82.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. SADETSKY N , Greene K, Cooperberg MR, Hubbard A, et al
    Impact of androgen deprivation on physical well-being in patients with prostate cancer: Analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry.
    Cancer. 2011 Mar 15. doi: 10.1002/cncr.26064.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. GRAFF JN , Beer TM
    Toward predictors of survival in castration-resistant prostate cancer.
    Cancer. 2011 Mar 9. doi: 10.1002/cncr.25986.
    PubMed     Text format     Related articles   
    
    
    
    
62. SONPAVDE G , Pond GR, Berry WR, de Wit R, et al
    The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
    Cancer. 2011 Mar 1. doi: 10.1002/cncr.25982.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. ALIBHAI SM
    Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates.
    Cancer. 2011 Mar 1. doi: 10.1002/cncr.25976.
    PubMed     Text format     Related articles   
    
    
    
    
64. MORGENTALER A
    Turning conventional wisdom upside-down: Low Serum testosterone and high-risk prostate cancer.
    Cancer. 2011 Mar 1. doi: 10.1002/cncr.25975.
    PubMed     Text format     Related articles   
    
    
    
    
65. WHITE A , Coker AL, Du XL, Eggleston KS, et al
    Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas.
    Cancer. 2011;117:1080-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
66. SIGUEL E
    Balancing the harms and benefits of early detection of prostate cancer.
    Cancer. 2011 Feb 11. doi: 10.1002/cncr.25922.
    PubMed     Text format     Related articles   
    
    
    
    
67. VAN LEEUWEN PJ , Connolly D
    Reply to Balancing the harms and benefits of early detection of prostate cancer.
    Cancer. 2011 Feb 11. doi: 10.1002/cncr.25920.
    PubMed     Text format     Related articles   
    
    
    
    
68. MADLUNG A , Simcock M, Ghadjar P
    Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Cancer. 2011 Feb 1. doi: 10.1002/cncr.25949.
    PubMed     Text format     Related articles   
    
    
    
    
69. COOPERBERG MR , Vickers AJ, Carroll PR
    Reply to comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Cancer. 2011 Feb 1. doi: 10.1002/cncr.25947.
    PubMed     Text format     Related articles   
    
    
    
    
70. TROCK BJ , Walsh PC
    Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.
    Cancer. 2011;117:656.
    PubMed     Text format     Related articles   
    
    
    
    January 2011
71. HOLZBEIERLEIN JM
    Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
    Cancer. 2011 Jan 24. doi: 10.1002/cncr.25899.
    PubMed     Text format     Related articles   
    
    
    
    
72. REESE AC , Sadetsky N, Carroll PR, Cooperberg MR, et al
    Inaccuracies in assignment of clinical stage for localized prostate cancer.
    Cancer. 2011;117:283-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. NGUYEN PL , Chen MH, Goldhaber SZ, Martin NE, et al
    Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation.
    Cancer. 2011;117:406-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. BOORJIAN SA , Karnes RJ, Viterbo R, Rangel LJ, et al
    Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.
    Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
75. HARZSTARK AL , Rosenberg JE, Weinberg VK, Sharib J, et al
    Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. COOPERBERG MR , Carroll PR, Vickers AJ
    Reply to Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
77. FROEHNER M
    Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
78. JAYADEVAPPA R , Chhatre S, Johnson JC, Malkowicz SB, et al
    Variation in quality of care among older men with localized prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
79. HEMELRIJCK MV , Garmo H, Holmberg L, Walldius G, et al
    Prostate cancer risk in the swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. CHU DI , Freedland SJ
    Metabolic risk factors in prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
81. DASKIVICH TJ , Chamie K, Kwan L, Labo J, et al
    Overtreatment of men with low-risk prostate cancer and significant comorbidity.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. REESE AC , Sadetsky N, Carroll PR, Cooperberg MR, et al
    Inaccuracies in assignment of clinical stage for localized prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. SMITH MR , Cook R, Lee KA, Nelson JB, et al
    Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
84. WHITE A , Coker AL, Du XL, Eggleston KS, et al
    Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
85. ANEES M , Horak P, El-Gazzar A, Susani M, et al
    Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
86. ALICIKUS ZA , Yamada Y, Zhang Z, Pei X, et al
    Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
87. ANDRIOLE GL , Kibel AS
    Editorial for "prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50"
    Cancer. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
88. FREEDLAND SJ
    Screening, risk assessment, and the approach to therapy in patients with prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
89. LILJA H , Cronin AM, Dahlin A, Manjer J, et al
    Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
90. PRINTZ C
    Nanoparticle PSA test helps predict likelihood of prostate cancer recurrence.
    Cancer. 2010;116:4669.
    PubMed     Text format     Related articles   
    
    
    
    
91. GARCIA JA , Hutson TE, Shepard D, Elson P, et al
    Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
92. HURWITZ MD , Hansen JL, Prokopios-Davos S, Manola J, et al
    Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
93. PICUS J , Halabi S, Kelly WK, Vogelzang NJ, et al
    A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
94. OH WK , Vargas R, Jacobus S, Leitzel K, et al
    Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
95. VAN LEEUWEN PJ , Connolly D, Tammela TL, Auvinen A, et al
    Balancing the harms and benefits of early detection of prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
96. BEARD C , Stason WB, Wang Q, Manola J, et al
    Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
97. ZILLI T , Chagnon M, Van Nguyen T, Bahary JP, et al
    Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
98. SCHREIBER D , Rineer J, Yu JB, Olsheski M, et al
    Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
99. MAJID S , Dar AA, Saini S, Yamamura S, et al
    MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer.
    Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
100. SNYDER CF , Frick KD, Blackford AL, Herbert RJ, et al
     How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?
     Cancer. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
101. COOPERBERG MR , Vickers AJ, Broering JM, Carroll PR, et al
     Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
     Cancer. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     July 2010
102. ROTH AJ , Nelson C, Rosenfeld B, Scher H, et al
     Methylphenidate for fatigue in ambulatory men with prostate cancer.
     Cancer. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. HAMILTON RJ , Banez LL, Aronson WJ, Terris MK, et al
     Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.
     Cancer. 2010;116:3389-98.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: